2Q19 Galafold® (migalastat) Revenue of
Growth Since Launch Driven by Continued Strong Global Uptake
Reiterating FY19 Revenue Guidance of
Full Enrollment in Pompe Pivotal Study of AT-GAA on Track by YE19
Significant Progress Across Industry Leading Rare Disease Gene Therapy Portfolio
Strong Balance Sheet with $575M+ Cash
Conference Call and Webcast Today at
Corporate Highlights for 2Q19 and Early 3Q19
- Global revenue for Fabry precision medicine Galafold in the second quarter of 2019 was
$44.1 millionand continues to track toward full-year 2019 revenue guidance of $160 million to $180 million. Now expecting to exceed 1,000 patients on therapy well before year-end. Second quarter revenue represented a year-over-year increase of 107% from total revenue of $21.3 millionin the second quarter of 2018, and a quarter over-quarter increase of 30% from total revenue of $34.0 millionin the first quarter of 2019. As of June 30, 2019, Galafold represented an estimated 24% of global market share of treated amenable patients. Global compliance and adherence rates continue to exceed 90%.
- Enrollment momentum in ongoing pivotal PROPEL study in Pompe disease at participating sites in 29 countries. This global study at the leading Pompe centers in the world is on track to achieve full enrollment of ~100 patients by year-end 2019. The study is now more than a majority enrolled. The Pompe patient and physician community around the world continues to show strong interest in AT-GAA, which has U.S. Breakthrough Therapy Designation, as the next potential standard of care.
- Positive interim Phase 1/2 clinical data for gene therapy in CLN6 Batten disease. The results for our AAV-CLN6 gene therapy showed a positive impact on motor and language function in seven of eight patients with available efficacy data (treated from 16 to 25 months), compared to a natural history dataset, as well as in comparisons within sibling pairs.
- Strategic partnerships with Catalent Biologics and
Thermo Fisherfor clinical and commercial gene therapy manufacturing. Brammer Bio, a part of Thermo Fisher, is assisting with clinical and commercial-scale capabilities for Amicus gene therapy programs in CLN6 and additional forms of Batten disease. Paragon Gene Therapy, a unit of Catalent Biologics, will support clinical manufacturing capabilities and capacity for multiple active preclinical lysosomal disorder programs in collaboration with Penn.
- Major expansion of gene therapy collaboration with the
Perelman School of Medicineat the University of Pennsylvania( Penn). Amicus now has exclusive worldwide rights to Penn’s next generation gene therapy technologies for a majority of lysosomal disorders and 12 additional rare diseases, including Rett Syndrome, Angelman Syndrome, Myotonic Dystrophy and select other muscular dystrophies.
- Positive initial proof-of-concept for preclinical Pompe gene therapy data at
American Society of Cell and Gene Therapymeeting. Positive preclinical results showed robust uptake and glycogen reduction in multiple tissues, including brain and spinal cord, and were a key driver for the expanded Amicus-Penn collaboration. Additional Pompe preclinical studies and selection of a clinical candidate are on track in 2019.
- Exclusive license for Japanese rights to
Ultragenyx’s(Nasdaq: RARE) Mepsevii™ (vestronidase alfa), an enzyme replacement therapy (ERT) for the lysosomal disorder Mucopolysaccharidosis type VII (MPS VII, Sly syndrome). Amicus will leverage its existing infrastructure, relationships, and experience in clinical development, regulatory approvals, and commercialization in Japan. Mepsevii™ is currently approved for the treatment of children and adults with MPS VII in the U.S., EU, and Brazil. Amicus plans to use the existing Mepsevii data package, as well as data from an ongoing investigator-sponsored trial in Japan, to support a J-NDA submission.
- Strong financial position to continue executing the Galafold launch, advance development programs and build leadership position in gene therapy science, development and manufacturing capabilities and capacity. The current cash position of
$575.7 millionat June 30, 2019, which includes $189.0 millionin net proceeds raised from our June 2019public offering of common stock, is expected to fund ongoing operations into 2021.
2Q19 Financial Results
- Total revenue in the second quarter 2019 was
$44.1 million, a year-over-year increase of 107% from total revenue of $21.3 millionin the second quarter of 2018, and a quarter over-quarter increase of 30% from total revenue of $34.0 millionin the first quarter of 2019. This includes year-over-year operational revenue growth measured at constant currency exchange rates of 115%, offset by a negative currency impact of $1.7M, or 8%.
- Cash, cash equivalents, and marketable securities totaled
$575.7 millionat June 30, 2019, compared to $504.2 millionat December 31, 2018.
- Total operating expenses of
$115.2 millionfor the second quarter of 2019 increased as compared to $65.1 millionin the second quarter of 2018, reflecting continued investments in the Galafold launch, Pompe clinical study program, and our gene therapy pipeline.
- Net loss was
$84.6 million, or $0.36per share, compared to a net loss of $61.8 million, or $0.33per share, for the second quarter 2018.
2019 Key Strategic Priorities
- Nearly double annual worldwide revenue for Galafold (FY19 guidance of
$160 million to $180 million) with over 1,000 Fabry patients on Galafold by year end.
- Complete enrollment in pivotal Phase 3 PROPEL clinical study in Pompe disease and report additional Phase 2 data.
- Report additional two-year results from Phase 1/2 clinical study in CLN6 Batten disease and complete enrollment in ongoing CLN3 Batten disease Phase 1/2 study.
- Establish preclinical proof of concept for Fabry and Pompe gene therapies.
- Maintain a strong financial position.
2019 Financial Guidance
For the full-year 2019 the Company anticipates total Galafold revenue of
Cash, cash equivalents, and marketable securities totaled
Anticipated 2019 Milestones by Program
Galafold Oral Precision Medicine for Fabry Disease
- Continued growth in global market share of treated amenable patients.
- Geographic expansion following recent approval in
- On track to meet full-year 2019 revenue guidance range of
$160 million to $180 million. Targetof 1,000+ patients on Galafold before year-end.
AT-GAA for Pompe Disease
- Initial 6-month data in additional ERT-switch patients (Cohort 4) and full 24-month data from the first three cohorts in Phase 1/2 ATB200-02 clinical study at
World Muscle Society, October 1-5, 2019( Copenhagen, Denmark)
- Retrospective natural history study data in approximately 100 ERT-treated Pompe patients.
- Additional supportive studies, including an open-label study in pediatric patients.
- Full enrollment in Phase 3 PROPEL clinical study.
- Advance agreed upon CMC requirements to support BLA.
Gene Therapy Pipeline:
- Detailed data presentation of interim clinical results in CLN6 Batten disease at Amicus Analyst Day on
October 10, 2019( New York, NY) and in a poster at Child Neurology SocietyAnnual Meeting, October 23-26, 2019( Charlotte, NC).
- Advancement of clinical, regulatory and manufacturing activities for CLN6 Batten disease
- High dose cohort on track to commence in Phase 1/2 clinical study of CLN3 Batten disease with full enrollment by year end.
- Additional preclinical data including next-generation gene therapies for Fabry and Pompe.
- Continued advancement of preclinical gene therapy programs in CLN8 and CLN1 Batten disease.
- Selection of Pompe AAV gene therapy clinical candidate to move into IND-enabling studies.
- Selection of Amicus site for late process development and manufacturing facilities.
Conference Call and Webcast
A live audio webcast can also be accessed via the Investors section of the
Galafold® (migalastat) 123 mg capsules is an oral pharmacological chaperone of alpha-Galactosidase A (alpha-Gal A) for the treatment of Fabry disease in adults who have amenable GLA variants. In these patients, Galafold works by stabilizing the body’s own dysfunctional enzyme so that it can clear the accumulation of disease substrate. Globally,
U. S. INDICATIONS AND USAGE
Galafold is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene (GLA) variant based on in vitro assay data.
This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
U.S. IMPORTANT SAFETY INFORMATION
The most common adverse reactions reported with Galafold (≥10%) were headache, nasopharyngitis, urinary tract infection, nausea and pyrexia.
USE IN SPECIFIC POPULATIONS
There is insufficient clinical data on Galafold use in pregnant women to inform a drug-associated risk for major birth defects and miscarriage. Advise women of the potential risk to a fetus.
It is not known if Galafold is present in human milk. Therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Galafold and any potential adverse effects on the breastfed child from Galafold or from the underlying maternal condition.
Galafold is not recommended for use in patients with severe renal impairment or end-stage renal disease requiring dialysis.
The safety and effectiveness of Galafold have not been established in pediatric patients.
To report Suspected Adverse Reactions, contact
For additional information about Galafold, including the full U.S. Prescribing Information, please visit https://www.amicusrx.com/pi/Galafold.pdf.
EU Important Safety Information
Treatment with Galafold should be initiated and supervised by specialists experienced in the diagnosis and treatment of Fabry disease. Galafold is not recommended for use in patients with a nonamenable mutation.
- Galafold is not intended for concomitant use with enzyme replacement therapy.
- Galafold is not recommended for use in patients with Fabry disease who have severe renal impairment (<30 mL/min/1.73 m2). The safety and efficacy of Galafold in children 0–15 years of age have not yet been established.
- No dosage adjustments are required in patients with hepatic impairment or in the elderly population.
- There is very limited experience with the use of this medicine in pregnant women. If you are pregnant, think you may be pregnant, or are planning to have a baby, do not take this medicine until you have checked with your doctor, pharmacist, or nurse.
- While taking Galafold, effective birth control should be used. It is not known whether Galafold is excreted in human milk.
- Contraindications to Galafold include hypersensitivity to the active substance or to any of the excipients listed in the PRESCRIBING INFORMATION.
- It is advised to periodically monitor renal function, echocardiographic parameters and biochemical markers (every 6 months) in patients initiated on Galafold or switched to Galafold.
- OVERDOSE: General medical care is recommended in the case of Galafold overdose.
- The most common adverse reaction reported was headache, which was experienced by approximately 10% of patients who received Galafold. For a complete list of adverse reactions, please review the SUMMARY OF PRODUCT CHARACTERISTICS.
- Call your doctor for medical advice about side effects.
For further important safety information for Galafold, including posology and method of administration, special warnings, drug interactions and adverse drug reactions, please see the European SmPC for Galafold available from the EMA website at www.ema.europa.eu.
Non-GAAP Financial Measures
Operational revenue growth excluding the impact of foreign currency exchange rates is a non-GAAP financial measure and should not be considered a replacement for, and should be read together with, the most comparable GAAP financial measure.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, manufacturing and supply plans, financing plans, and the projected revenues and cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the
Vice President, Investor Relations and Corporate Communications
Director, Corporate Communications
Amicus Therapeutics, Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)
|Three Months Ended June 30,||Six Months Ended June 30,|
|Net product sales||$||44,130||$||21,309||$||78,176||$||38,005|
|Cost of goods sold||5,367||3,135||9,422||5,750|
|Research and development||70,981||34,660||135,574||75,458|
|Selling, general, and administrative||42,578||29,172||86,881||56,568|
|Changes in fair value of contingent consideration payable||480||300||1,863||1,400|
|Depreciation and amortization||1,154||973||2,145||1,942|
|Total operating expenses||115,193||65,105||226,463||135,368|
|Loss from operations||(76,430||)||(46,931||)||(157,709||)||(103,113||)|
|Other income (expense):|
|Loss on exchange of convertible notes||(4,501||)||—||(40,624||)||—|
|Change in fair value of derivatives||—||(7,600||)||—||(2,739||)|
|Other income (expense)||(877||)||(5,316||)||209||(2,554||)|
|Loss before income tax||(83,834||)||(61,494||)||(203,965||)||(112,804||)|
|Income tax (expense) benefit||(717||)||(339||)||(885||)||1,053|
|Net loss attributable to common stockholders||$||(84,551||)||$||(61,833||)||$||(204,850||)||$||(111,751||)|
|Net loss attributable to common stockholders per common share —
basic and diluted
|Weighted-average common shares outstanding — basic and diluted||238,089,824||188,621,423||225,848,013||182,303,128|
Amicus Therapeutics, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share amounts)
|Cash and cash equivalents||$||220,578||$||79,749|
|Investments in marketable securities||355,078||424,403|
|Prepaid expenses and other current assets||20,116||16,592|
|Total current assets||634,876||551,096|
|Operating lease right-of-use assets, less accumulated amortization of $2,641 and $0 at June 30,
2019 and December 31, 2018, respectively
|Property and equipment, less accumulated depreciation of $16,890 and $15,671 at June 30,
2019 and December 31, 2018, respectively
|In-process research & development||23,000||23,000|
|Other non-current assets||12,035||6,683|
|Liabilities and Stockholders’ Equity|
|Accounts payable, accrued expenses, and other current liabilities||$||84,119||$||80,625|
|Operating lease liabilities||2,678||—|
|Total current liabilities||89,547||86,125|
|Senior secured term loan||146,994||146,734|
|Contingent consideration payable||21,247||19,700|
|Deferred income taxes||6,465||6,465|
|Operating lease liabilities||36,259||—|
|Other non-current liabilities||3,987||2,853|
|Commitments and contingencies|
|Common stock, $0.01 par value, 500,000,000 shares authorized, 254,513,522 and
189,383,924 shares issued and outstanding at June 30, 2019 and December 31, 2018,
|Additional paid-in capital||2,201,447||1,740,061|
|Accumulated other comprehensive loss:|
|Foreign currency translation adjustment||352||495|
|Unrealized gain (loss) on available-for-sale securities||355||(427||)|
|Total stockholders’ equity||600,058||342,912|
|Total Liabilities and Stockholders’ Equity||$||918,033||$||789,951|
Source: Amicus Therapeutics, Inc.